Results 81 to 90 of about 32,846 (250)

Untargeted metabolomics reveals the impact of Liraglutide treatment on metabolome profiling and metabolic pathways in type-2 diabetes mellitus

Saudi Pharmaceutical Journal
Liraglutide, a type2 diabetes mellitus (T2DM)-related treatment, improves glycemic control and reduces the risks of adverse cardiovascular events in T2DM patients.
Hicham Benabdelkamel, Rajaa Sebaa, Reem H. AlMalki, Afshan Masood, Assim A. Alfadda, Anas M. Abdel Rahman   +5 more
doaj   +1 more source

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine [PDF]

, 2019
Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global epidemic. In order to achieve optimal glucose control, it is often necessary to rely on combination therapy of multiple drugs or insulin because uncontrolled ...
Andreozzi, F, Mannino, Gc, Sesti, G
core   +1 more source

Research progress on the role of inflammatory mediators in the pathogenesis of epilepsy

Ibrain, Volume 11, Issue 1, Page 44-58, Spring 2025.
In the central nervous system, activated immune cells lead to the overproduction of inflammatory mediators through the corresponding signal pathway. Under the stimulation of inflammatory factors, neuroinflammation ultimately occurs. Overexpression of inflammatory mediators and activated immunocytes plays an important role in the emergence and ...
Yue Yu, Fei‐Ji Sun
wiley   +1 more source

Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways

Saudi Pharmaceutical Journal, 2020
Gefitinib is an effective treatment for patients with locally advanced non-small cell lung cancer. However, it is associated with cardiotoxicity that can limit its clinical use.
Abdullah F. AlAsmari, Nemat Ali, Fawaz AlAsmari, Wael A. AlAnazi, Musaad A. AlShammari, Naif O. Al-Harbi, Ali Alhoshani, Homood M. As Sobeai, Mohammed AlSwayyed, Mohammed M. AlAnazi, Nader S. AlGhamdi   +10 more
doaj   +1 more source

Pediatric Obesity: Influence on Drug Dosing and Therapeutics [PDF]

, 2018
Obesity is an ongoing global health concern and has only recently been recognized as a chronic disease of energy homeostasis and fuel partitioning. Obesity afflicts 17% of US children and adolescents.
Ameer, Barbara, PharmD, MBA, BCPS, FCP, Weintraub, Michael, MD   +1 more
core   +1 more source

Insulin Resistance: An Update on Biochemical and Pathophysiological Mechanisms and Impact on Various Diseases

iNew Medicine, EarlyView.
ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little, Stefan Offermanns, Haaglim Cho, Zhiping Liu, Pinglian Yang, Qiaozhu Su, Henry Wade, Wah Yang, Danielle Kamato, Neale Cohen, Alex Bobik, Iqra Ilyas, Suowen Xu   +12 more
wiley   +1 more source

Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials

Clinical and Experimental Hypertension, 2020
The antidiabetic effect of liraglutide in patients with type 2 diabetes mellitus has been explored in several trials. We performed this meta-analysis determining the effects of liraglutide on blood pressure in these patients.
Di Zhao, Hui Liu, Pingshuan Dong
doaj   +1 more source

Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial. [PDF]

Clin Obes
ABSTRACT Obstructive sleep apnea (OSA) is associated with chronic obstructive pulmonary disease (COPD) and obesity, and all three are linked to reduced health‐related quality of life (HRQoL). Coexistence of OSA and COPD increases morbidity and mortality compared to each condition alone.
Wolsing SK, Dogan ADA, Juhl CB, Hess S, Jensen TT, Bladbjerg EM, Hilberg O.   +6 more
europepmc   +2 more sources

Preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction‐associated steatotic liver disease treated with semaglutide: A case series

JPGN Reports, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects 30%–40% of youth with obesity and lacks approved pharmacologic therapies. In this single‐center retrospective case series at a tertiary care safety‐net children's hospital, we evaluated five adolescents (mean age: 17.0 years; 100% Hispanic; 60% male; mean body mass index:
Rachel Schenker, Katya Fomenko, Fotini T. Mitsinikos, Alaina P. Vidmar   +3 more
wiley   +1 more source

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study. [PDF]

, 2017
INTRODUCTION: Although liraglutide is widely recognized to have glycemic and extra-glycemic effects, few studies have compared these effects in relation to hypoglycemic treatment starting from the diagnosis of diabetes. We evaluated the effectiveness of
Ciresi A, Giordano C., Pantò F, Radellini S, Vigneri E   +4 more
core   +2 more sources